致心律失常性右心室发育不良/心肌病结构进展的评估
这项跨大西洋注册队列研究回顾性比较了85例符合2010年任务force诊断标准的致心律失常性右心室发育不良/心肌病患者首次与末次超声心动图,发现右心室流出道内径增大、右心室面积变化分数和左心室射血分数下降,结构进展存在显著个体差异,右心室进展与基线除极标准相关,左心室进展与磷酸受纳蛋白突变相关,结构进展与新发心电图诊断标准无关。
要点
- 平均随访6.4年,右心室流出道内径从35mm增至37mm,右心室面积变化分数从39%降至34%。
- 左心室射血分数从55%降至54%,结构进展存在显著个体差异。
- 右心室进展与基线除极标准相关(OR 9.0),左心室进展与磷酸受纳蛋白突变相关(OR 8.8)。
核心结论
- 致心律失常性右心室发育不良/心肌病的结构功能障碍呈进行性,且个体间差异显著。
- 右心室显著结构进展与既往除极异常相关,左心室进展受遗传背景影响。
- 结构进展与新发心电图诊断标准无关。
研究设计与样本
- 这项队列研究回顾性比较了来自跨大西洋致心律失常性右心室发育不良/心肌病注册登记的85例符合2010年任务force诊断标准患者的首次和末次可用超声心动图。
- 基线平均(标准差)年龄为42.8(14.4)岁,47例(55%)为男性。
- 平均(标准差)随访时间为6.4(2.5)年。
主要发现
- 右心室流出道内径从35 mm(四分位距31至39)增至37 mm(四分位距33至41)(P < .001)。
- 右心室面积变化分数从39%(四分位距33%至44%)降至34%(四分位距24%至42%)(P < .001),变化率为每5年-3.3%(四分位距-8.9%至1.2%)。
- 左心室射血分数从55%(四分位距52%至60%)降至54%(四分位距49%至57%)(P = .001),变化率为每5年-0.2%(四分位距-6.5%至1.7%)。
- 超过测量误差±2个标准差者定义为显著进展性疾病:右心室面积变化分数下降大于10%者21例,左心室射血分数下降大于7%者23例。
- 右心室疾病进展与基线除极标准相关(OR 9.0;95%CI 1.1-74.2;P = .04),左心室疾病进展与磷酸受纳蛋白(PLN)突变相关(OR 8.8;95%CI 2.1-37.2;P = .003)。
关键数值与推荐
- 右心室大小由右心室流出道内径确定,右心室和左心室收缩功能分别由右心室面积变化分数和左心室射血分数确定。
- 为建立测量误差,40份检查被重新分析。
- 结构进展的判定阈值为超过测量误差±2个标准差:右心室面积变化分数下降大于10%,左心室射血分数下降大于7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Considerable research has described the arrhythmic course of arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C). However, objective data characterizing structural progression, such as ventricular enlargement and cardiac dysfunction, in ARVD/C are relatively scarce. OBJECTIVES: To define the extent of structural progression, identify determinants of structural progression, and determine the association between structural progression and electrocardiographic (ECG) changes in patients with ARVD/C. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, first- and last-available echocardiograms of 85 patients with ARVD/C fulfilling 2010 Task Force diagnostic criteria (TFC) from a transatlantic ARVD/C registry were retrospectively compared to assess structural disease progression. Right ventricular (RV) size and systolic function between baseline and last follow-up were compared. The RV size was determined by RV outflow tract dimension, and RV and left ventricular (LV) systolic function were determined by RV fractional area change (RV-FAC) and LV ejection fraction (LVEF), respectively. Multivariable logistic regression was used to study associations between baseline characteristics and the occurrence of structural progression. MAIN OUTCOMES AND MEASURES: The main outcome was the change in variables indicating structural progression. Secondary outcomes were the correlation with electrical progression and identification of the association between baseline characteristics and occurence structural progression. RESULTS: Among the 85 patients with ARVD/C, mean (SD) age at baseline was 42.8 (14.4) years and 47 (55%) were men. After a mean (SD) follow-up of 6.4 (2.5) years, RV outflow tract dimension increased from 35 mm (interquartile range [IQR], 31 to 39) to 37 mm (IQR, 33 to 41) (P < .001), RV-FAC decreased from 39% (IQR, 33% to 44%) to 34% (IQR, 24% to 42%) (P < .001) (rate -3.3% per 5 years; IQR, -8.9% to 1.2%), indicating large interpatient variability. The LVEF decreased from 55% (IQR, 52% to 60%) to 54% (IQR, 49% to 57%) (P = .001) (rate, -0.2% per 5 years; IQR, -6.5% to 1.7%). Forty examinations were reanalyzed to establish the measurement error. Patients exceeding the measurement error by ±2 SDs were identified with significant progressive disease for RV, with a decrease in RV-FAC greater than 10% (n = 21) and, for LV, a decrease in LVEF greater than 7% (n = 23). Progression of RV disease was associated with depolarization criteria at baseline (odds ratio [OR], 9.0; 95% CI, 1.1-74.2; P = .04), whereas progression of LV disease was associated with phospholamban (PLN) mutation (OR, 8.8; 95% CI, 2.1-37.2; P = .003). There was no association between progressive RV/LV structural disease and newly developed ECG TFC. CONCLUSIONS AND RELEVANCE: Structural dysfunction in ARVD/C is progressive with substantial interpatient variability. Significant structural RV progression was associated with prior depolarization abnormalities, whereas LV progression is modified by genetic background. Structural progression was not associated with development of new ECG TFC. The results of this study pave the way for designing and launching trials aimed at reducing structural progression in patients with ARVD/C.
引用
- Mast TP, James CA, Calkins H, et al. Evaluation of Structural Progression in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy. JAMA Cardiol. 2017. PMID: 28097316. doi:10.1001/jamacardio.2016.5034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。